FUJIFILM Diosynth Signs Deal with TG Therapeutics
FUJIFILM Diosynth partners with TG Therapeutics for BRIUMVI® manufacturing, starting in 2025.
FUJIFILM Diosynth Biotechnologies has secured a multi-year manufacturing supply agreement with TG Therapeutics for BRIUMVI® (ublitiximab-xiiy), an FDA-approved treatment for relapsing forms of multiple sclerosis (RMS). This collaboration will involve secondary manufacturing support from FUJIFILM's new facility in Holly Springs, North Carolina, which is slated to begin operations in 2025.
The partnership highlights FUJIFILM's commitment to expanding its manufacturing capabilities to meet the growing demand for biotherapeutics, while TG Therapeutics sees this as a crucial step in securing a reliable supply chain for BRIUMVI as they enhance their commercialization efforts.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Curia New York recibe una carta de advertencia de la FDA por miles de inyecciones cromatográficas no documentadas
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Discussion